Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer

被引:256
|
作者
Zhu, Xinxin [1 ]
Lang, Jinghe [1 ]
机构
[1] Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Obstet & Gynecol, Beijing, Peoples R China
关键词
soluble; PD-1; PD-L1; tumor immunity; biomarker; CELL LUNG-CANCER; DEATH-LIGAND; PROGRAMMED DEATH-1; ANTITUMOR IMMUNITY; T-CELLS; HEPATOCELLULAR-CARCINOMA; CLINICAL-SIGNIFICANCE; POOR-PROGNOSIS; PD-1/PD-L1; BLOCKADE; CIRCULATING PD-L1;
D O I
10.18632/oncotarget.18311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The membrane-bound molecules programmed death 1 (PD-1) and its ligand PD-L1 (PD-1/PD-L1) belong to the immune checkpoint pathway. PD-1 pathway downregulates effector T cells in immune response, thereby causing immune suppression. Recent studies have revealed that membrane-bound PD-1 and PD-L1 also have soluble forms. These soluble forms increase the complexity and diversity of the composition and function of the PD-1/PD-L1 signaling pathway. However, the exact roles of these molecules remain unknown. The objective of this systematic review was to elucidate the biological significance of soluble PD-1/PD-L1 in human cancers and evaluate whether they are potential diagnostic, therapeutic, or prognostic biomarkers. We expect to provide new clues for future research on soluble PD-1/PD-L1 pathway in human malignant tumors.
引用
收藏
页码:97671 / 97682
页数:12
相关论文
共 50 条
  • [21] PD-1 AND PD-L1 EXPRESSION IN OVARIAN CANCER
    Wieser, V.
    Gaugg, I.
    Fleischer, M.
    Fiegl, H.
    Marth, C.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 64 - 64
  • [22] Antagonists of PD-1 and PD-L1 in Cancer Treatment
    Lipson, Evan J.
    Forde, Patrick M.
    Hammers, Hans-Berg
    Emens, Leisha A.
    Taube, Janis M.
    Topalian, Suzanne L.
    SEMINARS IN ONCOLOGY, 2015, 42 (04) : 587 - 600
  • [23] PD-1 and PD-L1 expression in ovarian cancer
    Wieser, V.
    Gaugg, I.
    Fleischer, M.
    Reimer, D.
    Zeimet, A.
    Fiegl, H.
    Marth, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [24] PD-1/PD-L1 and immunotherapy for pancreatic cancer
    Feng, Mengyu
    Xiong, Guangbing
    Cao, Zhe
    Yang, Gang
    Zheng, Suli
    Song, Xujun
    You, Lei
    Zheng, Lianfang
    Zhang, Taiping
    Zhao, Yupei
    CANCER LETTERS, 2017, 407 : 57 - 65
  • [25] PD-1/PD-L1 Pathway in Breast Cancer
    Schuetz, Florian
    Stefanovic, Stefan
    Mayer, Luisa
    von Au, Alexandra
    Domschke, Christoph
    Sohn, Christof
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (05) : 294 - 297
  • [26] Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer
    Ito, Shuhei
    Masuda, Takaaki
    Noda, Miwa
    Hu, Qingjiang
    Shimizu, Dai
    Kuroda, Yosuke
    Eguchi, Hidetoshi
    Tobo, Taro
    Utsunomiya, Tohru
    Mimori, Koshi
    ONCOLOGY, 2020, 98 (07) : 501 - 511
  • [27] PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?
    Inoue, Yusuke
    Osman, Murat
    Suda, Takafumi
    Sugimura, Haruhiko
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S199 - S202
  • [28] The Prognostic Significance of APOBEC3B and PD-L1/PD-1 in Nasopharyngeal Carcinoma
    Feng, ChangYin
    Zhang, YingYing
    Huang, JianPing
    Zheng, QiaoLing
    Yang, YingHong
    Xu, BenHua
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2021, 29 (03) : 239 - 244
  • [29] Prognostic significance of PD-L1 and PD-L2 in breast cancer
    Baptista, Mauricio Z.
    Sarian, Luis Otavio
    Derchain, Sophie F. M.
    Pinto, Glauce A.
    Vassal, Jose
    HUMAN PATHOLOGY, 2016, 47 (01) : 78 - 84
  • [30] Expression Pattern of Immune Checkpoints PD-1 and PD-L1 in Retinoblastoma and ITS Prognostic Significance
    Singh, L.
    Kashyap, S.
    Sen, S.
    Rizvi, M. A.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S278 - S278